Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy. -

AIBILI - Association for Innovation and Biomedical Research on Light and Image0 个研究点开始时间: 2009年9月9日最近更新: 2016年1月18日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Key Inclusion Criteria:
•1.High-risk proliferative diabetic retinopathy (HR-PDR) eyes.
•2.BCVA at baseline > 20/320 (25 letters in the ETDRS Chart) in the study eye.
•3.Clear ocular media and adequate pupillary dilatation to permit good quality fundus photography.
•4.Intraocular pressure < 21 mmHg.
•GENERAL CRITERIA
•1.Type I, or Type II diabetic subjects as defined by the WHO criteria of either gender, and aged = 18 years .
•2.Women must be using effective contraception, be post-menopausal for at least 12 months prior to trial entry, or surgically sterile.
•3.Ability to provide written informed consent.
•4.Ability to return for all trial visits.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Key Exclusion Criteria:
•1.Eyes with prior scatter (panretinal) or focal/grid photocoagulation, within the previous 6 months.
•2.Fibrovascular proliferation with retinal traction.
•3.Other cause of retinal neovascularization (retinal vein occlusion, radiation retinopathy or others).
•4.Atrophy/scarring/fibrosis/ hard exudates involving the center of the macula.
•5.Subjects who have received YAG laser, or peripheral retinal cryoablation, or laser retinopexy (for retinal tears only), or focal/grid photocoagulation, within the previous 6 months.
•6.Significant media opacities, which might interfere with visual acuity, assessment of toxicity or fundus photography.
•7.Subjects should not be entered if there is likelihood that they will require cataract surgery within the following 1 year.
•8.Any intraocular surgery within 6 months before trial enrolment.
•9.Previous vitrectomy.
•10.HbA1C level >11% or recent signs of uncontrolled diabetes.
•11.Any of the following underlying systemic diseases:
•History or evidence of severe cardiac disease, e.g. NYHA Functional Class III or IV, clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction, or revascularization procedure within 6 months prior to baseline, or ventricular tachyarrhythmia requiring treatment.
•History or evidence of clinically significant peripheral vascular disease such as intermittent claudication or prior amputation.
•Clinically significant impaired renal function (serum creatinine >2.5 mg/dL or s/p renal transplant or receiving dialysis).
•Clinically significant impaired hepatic function.
•Stroke (within 12 months of trial entry).
•Any major surgical procedure within one month before trial enrolment.
•12.Previous radiation to the head in the region of the study eye.
•13.Any prior treatment with an investigational agent for diabetic retinopathy or anti-VEGF therapy (including intravitreal, subconjunctival or subtenons corticosteroids) during the past 90 days for any other condition.
•14.Known serious allergies to fluorescein used in angiography, or to components of Lucentis® formulation.
•15.Systolic BP > 170 (2 different readings) or diastolic BP > 100 (2 different readings).
•16.Acute ocular or periocular infection.
•17.Previous filtering surgery (e.g., trabeculectomy) or placement of a glaucoma drainage device (e.g., tube-shunt surgery).

研究者

发起方

AIBILI - Association for Innovation and Biomedical Research on Light and Image

相似试验

进行中（未招募）

不适用

Prospective, randomized, multi-center, open label phase III study to evaluate the efficacy and safety of immunosuppression following a heart-beating cadaveric renal transplantation based on the use of rabbit anti-T-lymphocyte serum, tacrolimus and mycophenolate, free of concomitant corticosteroids from the start of immunosuppression - IBERICArenal transplantation

EUCTR2005-004431-21-PTFresenius Biotech GmbH160

已完成

2 期

A open label, active control, phase 2 clinical study to evaluate immunogenicity, safety and tolerability of single heterologous booster dose of Protein Subunit Vaccine against SARS-CoV-2 Virus.

CTRI/2023/09/057398Reliance Life Sciences Pvt Ltd RLS200

尚未招募

2 期

Prospective, multi-center, randomized, open label, active controlled, seamless phase 2/phase3 clinical study to evaluate immunogenicity, safety and tolerability of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences Pvt Ltd. against SARS-CoV-2 Virus) and Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) administered as primary vaccination.SARS-CoV-2

PACTR202307772264605RELIANCE LIFE SCIENCE1,550

进行中（未招募）

1 期

EUCTR2009-016466-82-DECO.DON AG102

进行中（未招募）

1 期

Clinical trial to compare the efficacy and safety of the treatment with the autologous chondrocyte transplantation product co.don chondrosphere® (ACT3D-CS) with microfracture in subjects with cartilage defects of the knee

EUCTR2009-016466-82-PLCO.DON AG102